Osteoporosis in patients with hepatitis B receiving tenofovir disoproxil fumarate: Does fibroblast growth factor 23 play a role?

Authors :: van Oorschot E
Koc ÖM
Koek GH
Source :: Journal of hepatology [J Hepatol] 2024 Oct; Vol. 81 (4), pp. e196-e197. Date of Electronic Publication: 2024 May 03.
Publication Year :: 2024

Subjects :: Humans
Female
Antiviral Agents adverse effects
Antiviral Agents therapeutic use
Hepatitis B drug therapy
Male
Middle Aged
Hepatitis B, Chronic drug therapy
Tenofovir adverse effects
Tenofovir therapeutic use
Fibroblast Growth Factors blood
Osteoporosis chemically induced
Osteoporosis drug therapy
Fibroblast Growth Factor-23

Full Text Access

Tools